Kit Expression in Small Cell Carcinomas of the Lung: Effects of Chemotherapy

Modern Pathology

Volumn 16, Issue 10, 2003, Pages 1041-1047

  Rossi, Giulio ^a   Cavazza, Alberto ^c   Marchioni, Alessandro ^a   Migaldi, Mario ^a   Bavieri, Mario ^a   Facciolongo, Nicola ^c   Petruzzelli, Stefano ^a   Longo, Lucia ^c   Tamberi, Stefano ^c   Crinò, Lucio ^b  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b BELLARIA HOSPITAL   (Italy)

^c NONE

Author keywords

c kit Immunohistochemistry; CD117; Lung; Small cell carcinoma; STI571

Indexed keywords

CARBOPLATIN; CISPLATIN; ETOPOSIDE; PROTEIN TYROSINE KINASE; STEM CELL FACTOR; STEM CELL FACTOR RECEPTOR;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BRONCHUS CARCINOID; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER RECURRENCE; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL ARTICLE; FEMALE; GASTROINTESTINAL STROMAL TUMOR; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; LUNG ADENOCARCINOMA; LUNG SMALL CELL CANCER; MALE; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; PROTO ONCOGENE; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, SMALL CELL; CISPLATIN; ETOPOSIDE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-KIT; SURVIVAL RATE;

EID: 10744228657     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.MP.0000089780.30006.DE     Document Type: Article

References (41)

1. Travis WD, Travis LB, Devesa SS. Lung cancer. Cancer 1995; 75:191-202.
2. Adjel AA, Marks RS, Bonner JA. Current guidelines for the management of small cell lung cancer. Mayo Clin Proc 1999; 74:809-16.
3. Johnson BE. Management of small cell lung cancer. Clin Chest Med 2002;23:225-39.
4. Spiro SG, Porter JC. Lung cancer - where are we today? Current advances in staging and nonsurgical treatment. Am J Respir Crit Care Med 2002;166:1166-96.
5. Yarden Y, Kuang WJ, Yang-Feng T, et al. Human protooncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J 1987;6:3341-51.
6. Sekido Y, Obata Y, Ueda R, et al. Preferential expression of c-kit protooncogene transcripts in small cell lung cancer. Cancer Res 1991;51:2416-9.
7. Hibi K, Takahashi T, Sekido Y, et al. Coexpression of stem cell factor and the c-kit genes in small-cell lung cancer. Oncogene 1991;6:2291-6.
8. Natali PG, Nicotra MR, Sures I, et al. Expression of c-kit receptor in normal and transformed human nonlymphoid tissues. Cancer Res 1992;52:6139-43.
9. Rygaard K, Nakamura T, Spang-Thomsen M. Expression of the protooncogene c-met and c-kit and their ligands, hepatocyte growth factor/scatter factor and stem cell factor in SCLC cell lines and xenografts. Br J Cancer 1993;67:137-46.
10. Matsuda R, Takahashi T, Nakamura S, et al. Expression of the c-kit protein in human solid tumors and in corresponding fetal and adult normal tissues. Am J Pathol 1993;142:339-46.
11. Tsuura Y, Hiraki H, Watanabe K, et al. Preferential localization of c-kit product in tissue mast cells, basal cells of skin, epithelial cells of breast, small cell lung carcinoma and seminoma/dysgerminoma in human: immunohistochemical study on formalin-fixed, paraffin-embedded tissues. Virchows Arch 1994;424:135-41.
12. Krystal GW, Hines SJ, Organ CP. Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor. Cancer Res 1996;56:370-6.
13. Arber DA, Tamayo R, Weiss LM. Paraffin section detection of the c-kit gene product (CD117) in human tissues: value in the diagnosis of mast cell disorders. Hum Pathol 1998;28: 498-504.
14. Gibson PC, Cooper K. CD117 (KIT): a diverse protein with selective applications in surgical pathology. Adv Anat Pathol 2002;9:65-9.
15. Butnor KJ, Burchette JL, Sporn TA, et al. CD117 immunoreactivity in pleuropulmonary tumors [abstract 1317]. Mod Pathol 2002;31:316A.
16. McHale T, Litzky LA, Pasha TL, et al. Immunohistochemical detection of c-kit in neuroendocrine tumors of the lung [abstract 1352]. Mod Pathol 2002;31:324A.
17. Naeem M, Dahiya M, Clark JI, et al. Analysis of c-kit protein expression in small-cell lung carcinoma and its implication for prognosis. Hum Pathol 2002;33:1182-7.
18. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 2001;411:355-65.
19. Sekido Y, Takahashi T, Ueda R, et al. Recombinant human stem cell factor mediates chemotaxis of small-cell lung cancer cell lines aberrantly expressing the c-kit protooncogene. Cancer Res 1993;53:1709-14.
20. Plummer H, Catlett J, Leftwich J, et al. c-myc expression correlates with suppression of c-kit protooncogene expression in small cell lung cancer lines. Cancer Res 1993;53:4337-42.
21. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-7.
22. Savage DG, Antman KH. Imatinib mesylate - a new oral targeted therapy. N Engl J Med 2002;346:683-93.
23. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the thyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001;344: 1052-6.
24. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-80.
25. Heinrich MC, Blanke CD, Druker BJ, Corless CL. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 2002;20:1692-703.
26. Rubin BP, Schuetze SM, Eary JF, et al. Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J Clin Oncol 2002;20:3586-91.
27. Krystal GW, Honsawek S, Litz J, Buchdunger E. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. Clin Cancer Res 2000;6:3319-26.
28. Wang WL, Healy ME, Sattler M, et al. Growth inhibition and modulation of kinase pathways on small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI571. Oncogene 2000;19:3521-8.
29. Kijima T, Maulik G, Ma PC, et al. Regulation of cellular proliferation, cytoskeletal functions, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells. Cancer Res 2002;62:6304-11.
30. Zelen M. Key note address on biostatistic and data retrieval. Cancer Chemother Rep 1973;4:31-42.
31. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16.
32. Travis WD, Colby TV, Corrin B, et al. World Health Organization Pathology Panel: World Health Organization international histological typing of lung and pleural tumours. 3rd ed. Berlin: Springer-Verlag; 1999.
33. Carney DN. Lung cancer - time to move on from chemotherapy. N Engl J Med 2002;346:126-8.
34. Sekido Y, Fong KM, Minna JD. Progress in understanding the molecular pathogenesis of human lung cancer. Biochim Biophys Acta 1998;1378:F21-59.
35. Wistuba II, Gazdar AF, Minna JD. Molecular genetics of small cell lung carcinoma. Semin Oncol 2001;28(Suppl 4):3-13.
36. Arteaga CL, Khuri F, Krystal G, Sebti S. Overview of rationale and clinical trials with signal transduction inhibitors in lung cancer. Semin Oncol 2002;29(Suppl 4):15-26.
37. Dy GK, Adjei AA. Novel targets for lung cancer therapy: part I. J Clin Oncol 2002;20:2881-94.
38. Fong KM, Minna JD. Molecular biology of lung cancer: clinical implications. Clin Chest Med 2002;23:83-101.
39. Shivapurkar N, Virmani AK, Witsuba II, et al. Deletions of chromosome 4 at multiple sites are frequent in malignant mesothelioma and small cell lung carcinoma. Clin Cancer Res 1999;59:1973-9.
40. Heinrich MC, Rubin BP, Longley JB, Fletcher JA. Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. Hum Pathol 2002;33:484-95.
41. Johnson BE, Fisher B, Fisher T, et al. Phase II study of STI571 (Gleevec®) for patients with small cell lung cancer [abstract 1171]. Proc Am Soc Clin Oncol 2002;21:293a.